Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure

Electronic patient-reported outcome systems in oncology clinical practice

(2012) Antonia V. Bennett et al.   CA-A CANCER JOURNAL FOR CLINICIANS

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

(2012) A. Deisseroth et al.   CLINICAL CANCER RESEARCH

Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer

(2012) Michael J. Fisch et al.   JOURNAL OF CLINICAL ONCOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases

(2012) Louis S. Matza et al.   SUPPORTIVE CARE IN CANCER

Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful Patient-Reported Outcomes into Regulatory Trials and US Drug Labels

(2012) Ethan Basch   VALUE IN HEALTH

End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-Reported Outcomes in Supportive Care

(2011) Emma Bateman et al.   SEMINARS IN ONCOLOGY

End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences

(2010) Jennifer W. Mack et al.   JOURNAL OF CLINICAL ONCOLOGY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

How Long and How Well

(2010) Michael A. Kozminski et al.   MEDICAL DECISION MAKING

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

(2010) Robert H. Dworkin et al.   PAIN

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

(2009) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

The Brief Pain Inventory and Its “Pain At Its Worst in the Last 24 Hours” Item: Clinical Trial Endpoint Considerations

(2009) Thomas M. Atkinson et al.   PAIN MEDICINE

Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer

(2008) Susan Halabi et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Trials in palliative treatment—have the goal posts been moved?

(2008) Peter Kirkbride et al.   LANCET ONCOLOGY